Transpek Inds. Q1 FY27 earnings call

Transpek Industry Limited reported a challenging Q1 FY27, with total revenue declining by 6.5% year-on-year to INR155.1 crores. EBITDA also saw a significant drop of 32.4% year-on-year, reaching INR24.1 crores, resulting in an EBITDA margin of 15.6%. Profit after tax for the quarter stood at INR8.9 crores, reflecting the impact of aggressive pricing, oversupply, and subdued demand in export markets.

Management announced a strategic shift from a conservative approach to more aggressive investment in growth, aiming to double the business size within the next five years. This includes doubling the R&D team and establishing a multi-purpose pilot plant in Ekalbara, expected to be ready by February 2027, to accelerate product development and scale-up. This shift is supported by a strong balance sheet with almost no debt and healthy cash reserves.

The company is actively diversifying its product portfolio beyond traditional acid and alkyl chlorides, focusing on higher value-added polymers, polymer modifiers, additives, sulfonation products, and chloro-fluoro intermediates. New acid chloride products are projected to increase revenue from INR4 crores in FY26 to INR15 crores in FY27. Additionally, two new polymer products are nearing commercialization, with one expected to generate INR50 crores annually starting Q4 FY27 and another INR50 crores by FY28.

To support future growth and overcome expansion limitations at its current Ekalbara site, Transpek is exploring a new manufacturing facility in Odisha. The company has expressed interest in land acquisition in a notified zone, with a detailed feasibility report being prepared for submission to the Odisha government. This greenfield project is estimated to cost INR250 crores over 5-6 years, with an expected payback period of 4-5 years, and is seen as crucial for future capacity additions.

The long-term contract with DuPont, now assigned to Arclin, continues without disruption, with renewal discussions expected to commence in late 2026. While management sees no reason for non-renewal, they are diversifying their portfolio to mitigate risk if the contract is not renewed. The company acknowledges competitive pressures in the aramid market but asserts that its focus on high-end, mission-critical applications and formula-based cost-plus pricing for key contracts helps sustain margins.

Despite being a net debt-free company with healthy cash reserves, management prioritizes reinvesting in growth initiatives over share buybacks, as suggested by an analyst. The company's significant INR300 crore investment in Silox remains illiquid due to a shareholder agreement, preventing immediate monetization for reinvestment, despite its low dividend yield of INR5-7 crores.